Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | ATF1 | P18846 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661177 | 0.85 | — | — | |
| SCHEMBL22211709 | 0.83 | — | — | |
| SCHEMBL22211711 | 0.83 | — | — | |
| SCHEMBL13019471 | 0.80 | TRPV1 (0.32) | — | |
| SCHEMBL26313680 | 0.77 | COMT (0.33) | COMTKDM5B | |
| SCHEMBL2424060 | 0.77 | CA2 (0.31) | — | |
| SCHEMBL83401 | 0.75 | — | — | |
| SCHEMBL19144473 | 0.74 | COMT (0.32) | COMT | |
| SCHEMBL939267 | 0.74 | ENPP3 (0.35) | — | |
| SCHEMBL6722883 | 0.74 | COMT (0.32) | COMTKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2014142273-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | 中外製薬株式会社 (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2488514-B1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| US-20040092402-A1 | Pyrimidine derivatives and herbicides containing the same | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| CN-1473155-A | Pyrimidine derivatives and herbicides containing the same | ס������ũҩ��ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| EP-1333029-A1 | PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THE SAME | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | CHRNA7, CHRNA5, CHRNA1 | COMT 213/4885KDM5B 490/4885ATF1 3147/4885 |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | COMT 202/4885KDM5B 532/4885ATF1 3091/4885 |
| US-20040092402-A1 | Pyrimidine derivatives and herbicides containing the same | DDX41, CBR3, DPYD | COMT 2735/4885KDM5B 1872/4885ATF1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.